Weight loss & metabolic health
FTPP (Adipotide)
An experimental peptide designed to attack the blood vessels that feed fat tissue. Tested in animals, including primates, where kidney effects were seen.
No human dose has ever been tested. In monkeys it caused kidney damage that grew with the dose. The protocol shown is the community reference (0.5–2 mg a day); uPrime uses 1 mg for the shortest 4-week cycle.
How it works
It homes in on a protein found on the blood vessels that feed white fat and triggers the death of those vessel cells. Without blood supply, the fat tissue shrinks.
What it is used for
Researched as an obesity treatment.
What the evidence says
Obese monkeys lost about 11% of their body weight in four weeks. A small human study started, but no clear results have been published.
Side effects and cautions
In monkeys it caused dehydration and kidney changes that went away after stopping. There is no human safety data.
Half-life
Not established in people
Makes sense for
- Research only: no human dose has been tested
Does not make sense for
- Anyone with a kidney problem
- Anyone looking for a safe fat-loss option
Boost the effect
- Drink plenty of water: protects the kidneys, its main risk